NCT03786289View on ClinicalTrials.gov

Study on Single Administration and Dose Increment of Recombinant Human Serum Albumin/Erythrocyte Fusion Protein for Injection

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 3, 2018

Primary Completion Date

July 3, 2019

Study Completion Date

December 9, 2019

Conditions

Healthy Subjects

Interventions

BIOLOGICAL

Recombinant human serum albumin/erythropoietin fusion protein

Recombinant human serum protein/erythropoietin fusion protein 150μg-1200μg single subcutaneous injection at Day1

BIOLOGICAL

Recombinant erythropoietin injection (CHO cells)

Recombinant erythropoietin injection (CHO cells) 10000IU single subcutaneous injection at Day1

Trial Locations (1)

100069

Beijing you 'an hospital affiliated to capital medical university, Beijing

All Listed Sponsors

lead

Tianjin SinoBiotech Ltd.

INDUSTRY

NCT03786289 - Study on Single Administration and Dose Increment of Recombinant Human Serum Albumin/Erythrocyte Fusion Protein for Injection | Biotech Hunter | Biotech Hunter